Author

Thomas Collot

Observed names: T. Collot, THOMAS COLLOT

Institution: Centre Hospitalier William Morey

Observed institutions: Inserm, Centre Georges François Leclerc, Université Bourgogne Franche-Comté, Genomic and Immunotherapy Medical Institute, Centre de recherche Translationnelle en Médecine moléculaire, Centre Hospitalier William Morey

ORCID: 0000-0003-4805-7682

Observed ORCID: 0000-0003-4805-7682

OpenAlex ID: A5073171914

Implementation and use of whole exome sequencing for metastatic solid cancer

2020 · Manon Réda, Corentin Richard, et al. · EBioMedicine · 49

PARP inhibitor resistance and TP53 mutations in patients treated with olaparib for BRCA-mutated cancer: Four case reports

2020 · Thomas Collot, Julie Niogret, et al. · Molecular Medicine Reports · 25

Quality of life and perceived burden of the primary caregiver of patients aged 70 and over with cancer 5 years after initial treatment

2023 · Jérémy Barben, Oumar Billa, et al. · Supportive Care in Cancer · 16

Bevacizumab-based Chemotherapy for Poorly-differentiated Neuroendocrine Tumors

2018 · THOMAS COLLOT, JEAN-DAVID FUMET, et al. · Anticancer Research · 16

FOLFIRINOX-3 plus bevacizumab (bFOLFIRINOX3) in chemo-refractory metastatic colorectal cancer: a multicenter phase II trial

2025 · Hélène Bellio, Nicolas Roussot, et al. · Future Oncology · 3

Efficacy and safety of pembrolizumab–lenvatinib in metastatic endometrial cancer: results from the French multicenter early access program

2026 · D. Bello Roufai, L. Mansi, et al. · ESMO Open

Pembrolizumab lenvatinib in metastatic uterine carcinosarcoma cohort: safety and efficacy from the french multicenter early access program subgroup (LARENA study)

2026 · Clémence Allirol-Binet, Laura Mansi, et al. · International Journal of Gynecological Cancer

Phase II of desynchronized irinotecan plus bevacizumab, oxaliplatin, 5-fluorouracil, and folinic acid (bFOLFIRINOX-3) administration in chemorefractory metastatic colorectal cancer patients.

2023 · Jean-David Fumet, Aurelie Bertaut, et al. · Journal of Clinical Oncology

An Algorithm Combining Patient Performance Status, Second Hit Analysis, PROVEAN and Dann Prediction Tools Could Foretell Sensitization to PARP Inhibitors in Digestive, Skin, Ovarian and Breast Cancers

2021 · Sandy Chevrier, Corentin Richard, et al. · Cancers

Works count: 9

Citation count: 109

H-index: 4

I10-index: 4